Description
General description
All ChIPAb+ antibodies are individually validated for chromatin precipitation, every lot, every time. Each ChIPAb+ antibody set includes control primers (tested every lot by qPCR) to biologically validate your IP results in a locus-specific context. The qPCR protocol and primer sequences are provided, allowing researchers to validate ChIP protocols when using our antibody in their chromatin context. Each set also includes a negative control antibody to ensure specificity of the ChIP reaction.
The ChIPAb+ Sox-2, clone 6F1.2 antibody/primer set includes the Sox-2, clone 6F1.2 antibody, a negative control antibody (purified mouse IgG), and qPCR primers which amplify a 95 bp region within the promoter of the human nanog gene. The Sox-2, clone 6F1.2 antibody and negative control antibodies are supplied in a scalable "per ChIP" reaction size and can be used to functionally validate the precipitation of Sox-2-associated chromatin.
Sox-2 plays a key role in embryonic stem cell development, and has been shown to help stem cells maintain pluripotent potential. It has also been shown to be associated with uncommitted dividing stem cell and precursor cells of the developing CNS.
~34 kDa
Immunogen
Recombinant GST Fusion protein.
Application
Please refer to the EZ-Magna G ChIP (Cat. No. 17-409) or EZ-ChIP (Cat. No. 17-371) protocol for experimental details.
Research Category
Epigenetics & Nuclear Function
Research Sub Category
Chromatin Biology
Transcription Factors
This ChIPAb+ Sox-2, clone 6F1.2 -ChIP Validated Antibody & Primer Set conveniently includes the antibody & the specific control PCR primers.
Biochem/physiol Actions
Not tested in other species.
Recognizes Sox-2, MW: ~34 kDa.
Packaging
25 assays per set. Recommended use: ~4 μg antibody per chromatin immunoprecipitation (dependent upon biological context).
Physical form
Format: Purified
Preparation Note
Stable for 1 year at -20°C from date of receipt. Handling Recommendations: Upon first thaw, and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.
Analysis Note
Chromatin Immunoprecipitation:
Sonicated chromatin prepared from Ntera 2 cells (3 X 10⁶ cell equivalents per IP) were subjected to chromatin immunoprecipitation using 4 µg of either a normal mouse IgG, or Anti-Sox-2, clone 6F1.2 antibody and the Magna ChIP® G Kit (Cat. No. 17-611). Successful immunoprecipitation of Sox-2-associated DNA fragments was verified by qPCR using ChIP Primers, nanog promoter (Figure 1).
Please refer to the EZ-Magna ChIP G (Cat. No. 17-409) or EZ-ChIP (Cat. No. 17-371) protocol for experimental details.
Control
Includes negative control mouse IgG antibody and primers specific for human nanog promoter region.
Other Notes
Anti-Sox-2, clone 6F1.2 (mouse monoclonal IgG), Part No. CS204373.
One vial containing 100 μg of protein A purified antibody in 140 μL of 0.02 M phosphate buffer pH 7.6 with 0.25 M NaCl containing 0.1% sodium azide, and 30% glycerol. Store at -20°C.
Normal Mouse IgG, Part No. CS200621.
One vial containing 125 μg of purified mouse IgG in 125 μL storage buffer containing 0.1% sodium azide. Store at -20°C.
ChIP Primers, nanog promoter,
Part No. CS204374. One vial containing 75 μL of 5 μM of each primer specific for the promoter region of human nanog.
Store at -20°C.
FOR: GTT CTG TTG CTC GGT TTT CT
REV: TCC CGT CTA CCA GTC TCA CC
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Legal Information
MAGNA CHIP is a registered trademark of Merck KGaA, Darmstadt, Germany
UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
